tbuckley/cabot-search huggingface dataset:
Guidelines, regulations, and clinical research.
Authors: E Frei, J R Clark, B G Fallon
Journal: Journal of Clinical Oncology (1986)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1986.4.7.1026 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3723164 Guidelines, regulations, and clinical research. E Frei 3rdxE Frei 3rdSearch for articles by this author , J R ClarkxJ R ClarkSearch for articles by this author , B G FallonxB G FallonSearch for articles by this author https://doi.org/10.1200/JCO.1986.4.7.1026 First Page PDF © 1986 by American Society of Clinical Oncology
Improved control of childhood asthma with low‐dose, short‐term vitamin D supplementation: a randomized, double‐blind, placebo‐controlled trial
Authors: H. Tachimoto, H. Mezawa, T. Segawa, N. Akiyama, H. Ida, M. Urashima
Journal: Allergy (2016)

Abstract Background In our prior randomized trial on preventing influenza, asthma attacks as a secondary outcome occurred less often in the vitamin D group than in the placebo group. We aimed to clarify whether low‐dose, short‐term vitamin D supplementation, in addition to standard treatments, improves control of childhood asthma. Methods We conducted a randomized, double‐blind, placebo‐controlled trial comparing vitamin D3 supplements (800 IU /day) with placebo for 2 months in schoolchildren with asthma. The primary outcomes were frequency and severity of asthma judging from changes in asthma control levels defined by the Global Initiative for Asthma ( GINA ) by collaborating doctors at 2 and 6 months. Results Japanese schoolchildren with asthma ( n = 89) were randomly assigned to receive vitamin D ( n = 54) or placebo ( n = 35). At 2 months, GINA asthma control was significantly more improved in the vitamin D group compared with the placebo group ( P = 0.015). Childhood asthma control test ( CACT ) scores, a secondary outcome, were also significantly ( P = 0.004) improved in the vitamin D group compared with the placebo group at 2 months, and differences remained significant ( P = 0.012) at 6 months. The proportion of patients with a peak expiratory flow rate &lt;80% predicted was significantly less in the vitamin D group (8/54: 15%) than in the placebo group (12/35: 34%) at 6 months ( P = 0.032). Conclusions Low‐dose, short‐term vitamin D supplementation in addition to standard treatment may improve levels of asthma control in schoolchildren.
Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2.
Authors: R Torra, C Badenas, A Darnell, C Nicolau, V Volpini, L Revert, X Estivill
Journal: Journal of the American Society of Nephrology (1996)

Linkage analysis was performed on 49 Catalan families with autosomal dominant polycystic kidney disease obtained via the Nephrology Department and related nephrology centers. A total of 336 subjects, 267 at risk for the disease, were investigated using three microsatellites linked to polycystic kidney disease Type 1 (PKD1) and three microsatellites linked to PKD2. All of the subjects underwent physical and sonographic examination. The results demonstrate locus heterogeneity, with 0.85 as the maximum likelihood for the proportion of families linked to PKD1. All of the remaining families were found to be linked to PKD2. Analysis of clinical data in the PKD1 group (N = 146) versus the PKD2 group (N = 20) showed a milder form of the disease in the latter, with a later age at diagnosis (27.4 versus 41.4 yr, P = 0.0002), later age of onset of ESRD (53.4 versus 72.7 yr, P < 0.0001), later age of diagnosis of hypertension (34.8 versus 49.7 yr, P = 0.001) and lower prevalence of hypertension at younger ages. Sonographic findings did not differ significantly between both groups. Although anticipation was observed in both groups, it did not affect the majority of families. No signs of imprinting were found in this study, and the only gender effect was an earlier age of onset of ESRD in men than in women (49.5 versus 53.1 yr in PKD1, P < 0.01 and 70.57 versus 73.6 yr in PKD2, P = 0.1). Molecular analysis of autosomal-dominant polycystic kidney disease allows presymptomatic diagnosis in individuals younger than age 30, and helps in establishing prognosis.
In Vitro Studies of Chemical Mutagens and Carcinogens. I. Stability Studies in Cell Culture Medium2
Authors: Erling M. Jensen, Robert J. LaPolla, Paul E. Kirby, Steve R. Haworth
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article In Vitro Studies of Chemical Mutagens and Carcinogens. I. Stability Studies in Cell Culture Medium Get access Erling M. Jensen, Erling M. Jensen Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert J. LaPolla, Robert J. LaPolla Search for other works by this author on: Oxford Academic PubMed Google Scholar Paul E. Kirby, Paul E. Kirby Search for other works by this author on: Oxford Academic PubMed Google Scholar Steve R. Haworth Steve R. Haworth Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 3, September 1977, Pages 941–944, https://doi.org/10.1093/jnci/59.3.941 Published: 01 September 1977 Article history Received: 22 November 1976 Accepted: 07 April 1977 Published: 01 September 1977
Mutant Nucleophosmin 1(NPMc+) Mislocalizes The p40 Isoform Of The Master Myeloid Transcriptional Regulator C/EBPα To The Cytoplasm: Implications In AML
Authors: Nirmalee Abayasekara, Czepiel Kathryn, Lee Jaclyn, Anjali Khanna, Nancy Berliner, Arati Khanna-Gupta
Journal: Blood (2013)
Combination therapy with etanercept and rituximab in relapsed CLL/SLL
Authors: J. A. Woyach, M. S. Lucas, N. A. Heerema, M. E. Moran, D. M. Lucas, D. Young, M. A. Caligiuri, T. S. Lin, J. C. Byrd
Journal: Journal of Clinical Oncology (2008)

7065 Background: Rituximab has modest activity in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) but is associated with TNF-α release that can cause CLL proliferation and inhibit apoptosis. We examined whether disruption of TNF-a signaling by etanercept would improve response duration to rituximab in CLL. Methods: Eligible adult patients (pts) had previously treated CLL with a performance status 0–3. Pts received etanercept 25 mg subcutaneously twice weekly (weeks 1–5) and rituximab 375 mg/m2 intravenously three times weekly (weeks 2–5). Primary endpoints were response, toxicity, and progression-free survival (PFS). An abbreviated phase I followed by a two-stage phase II design was used. Results: Between 11/02 and 6/06, 36 pts with CLL/SLL were enrolled. Pts had a median of 2 prior treatments, 50% were fludarabine-refractory, and 22% had del(17p13.1). 33 pts completed therapy, and 34 patients were evaluable for response. Using NCI 96 criteria, 10 pts (overall response rate [ORR] 29%) had responses including 9 partial responses and 1 complete remission. Response rate was not affected by prior rituximab treatment (ORR 33%) and fludarabine-refractory status (ORR 28%), but no responses were observed in pts with del(17p13.1). Median response duration was 12.3 (range 4–48) months and median PFS was 6.5 (range 1–52) months. 10 pts have had treatment-free intervals exceeding 12 months, including 3 who have remained untreated for 24, 35 and 48 months, respectively. Adverse events were mild, including grade 1/2 infusion reactions (39%), grade 3/4 cytopenias (anemia 3%, thrombocytopenia 19%, and neutropenia 33%), and grade 3 infections (14%). No CMV reactivation or opportunistic infections were observed. Conclusions: The combination of etanercept and thrice weekly rituximab produces durable remissions in non-del(17p13.1) CLL patients and is well tolerated. Future investigation of this combination therapy in elderly pts who are not candidates for aggressive chemoimmunotherapy should be pursued. No significant financial relationships to disclose.
P96 Longitudinal changes in renal function in liver transplant recipients: impact of acute kidney injury and the assessment of the decline in estimated glomerular filtration rate over 5 years post liver transplantation
Authors: A Slack, M McPhail, R Westbrook, N Heaton, M Heneghan, J O'Grady, V Aluvihare, K Agarwal, A Suddle, G Auzinger, W Bernal, C Willars, J Wendon
Journal: Gut (2010)

Introduction  Orthotopic liver transplantation (OLT) can valuably increase long term survival in patients with cirrhosis. After the immediate transplant period cardiovascular morbidity and mortality become increasingly important and chronic kidney disease (CKD) stage 3 or more has been described as an independent risk factor for cardiovascular adverse events. The effect of acute kidney injury (AKI) on long term mortality and the pattern of renal morbidity post OLT have not been well described.  Method  211 OLT recipients (median age 53 (20–70) years: 140 male; 71 female) for chronic liver disease were studied to assess longitudinal long term changes in renal function. The MDRD (version 4) equation was used to estimate glomerular filtration rate (eGFR) pre-OLT and at 1 week, 1 month, 6 months 1 year, 2 years and 5 years post-OLT. Acute Kidney Injury was defined according to Acute Kidney Injury Network criteria and CKD staging according to Kidney Dialysis Outcomes Quality Initiative criteria.  Results  Median follow-up was 2023 (3–3188) days and median survival was not reached in this study (76% 5 year survival). Median eGFR at time of transplant was 67 (29–149) ml/min/1.73 m 2  falling to 59 (24–165) ml/min/1.73 m 2  at 6 months post-OLT (p 2  at 5 years post-OLT (p 1 during the first week post OLT did not influence long term survival (HR 1.43 (95% CI 0.65 to 3.1, p=0.315, Kaplan–Meier method) neither did the use of renal replacement therapy post OLT (HR 1.56 (95% CI 0.60 to 4.1, p=0.268, KM method).  Conclusion  In this cohort a decline in eGFR of 10 ml/min/1.73 m 2  was noted over the 5 year follow-up; twice the rate of decline expected in the general population. The higher proportion of patients at CKD stage 3 or more at 5 years compared to pre-OLT suggest greater awareness of this potentially important risk factor for cardiovascular disease is required. AKI post-OLT was not associated with a higher risk of long term reduction in eGFR beyond 6 months post-OLT; nor did the use of RRT post-OLT impact on 5-year mortality.
Contralateral breast cancer risk in patients with familial breast cancer who tested negative for BRCA1 and BRCA2.
Authors: K. Rhiem, C. Engel, M. Graeser, W. Janni, M. Kiechle, N. Ditsch, C. Mundhenke, R. Kreienberg, J. Tio, M. Golatta, A. Honig, D. Gadzicki, D. Speiser, K. Kast, S. Briest, A. Meindl, R. Schmutzler
Journal: Journal of Clinical Oncology (2011)

1013 Background: A high incidence of contralateral breast cancer has been reported in patients with BRCA1or BRCA2 mutations while the risk in patients with familial non-BRCA-associated breast cancer remains unclear. This study was undertaken to estimate the risk for contralateral breast cancer in patients of BRCA1- and BRCA2-negative high risk families and to determine predictive risk factors. Methods: A retrospective, multicenter, cohort study was performed from 1996 until 2010 and comprised 3,580 women with unilateral breast cancer from 2,793 high-risk families who were tested negative for BRCA1 or BRCA2 mutations. Kaplan-Meier analysis was used to estimate age-dependent contralateral breast cancer risks. Cox regression analysis was applied to assess the impact of age at first breast cancer on contralateral breast cancer risk. Results: The cumulative risk for contralateral breast cancer 25 years after first breast cancer was 19% (95%CI 16% to 22%) for patients from families with non-BRCA-associated breast cancer. This rate is significantly lower compared to BRCA1 and BRCA2 mutation carriers (46% and 36%, respectively). Younger age at first breast cancer was associated with a significantly higher risk of contralateral breast cancer. After 25 years, 29% (95%CI 20% to 37%) of non-carriers who were younger than 40 years of age at first breast cancer developed contralateral breast cancer, compared with only 15% (95%CI 10% to 20%) of those who were older than 50 years. These incidences are similar to patients with sporadic breast cancer. Conclusions: Contralateral breast cancer risk in patients with familial non-BRCA-associated breast cancer is similar to the risk in patients with sporadic breast cancer and depends on age at first breast cancer. Therefore, risk-reducing contralateral mastectomy does not seem to be adequate for non-BRCA1/2 breast cancer patients.
Abstract 862: Association of non-steroidal anti-inflammatory drugs with colorectal cancer by subgroups in the Vitamins and Lifestyle (VITAL) Study
Authors: Xiaoliang Wang, Ulrike Peters, John D. Potter, Emily White
Journal: Cancer Research (2015)

Abstract Background: There is substantial evidence that use of non-steroidal anti-inflammatory drugs (NSAIDs) reduces the risk of colorectal cancer (CRC), but no subgroup has been identified for which the chemoprevention effect outweighs the risk of side effects. Methods: We tested the interaction between NSAID use and multiple risk factors on CRC risk in the VITAL cohort. A total of 73,458 individuals aged 50-76 completed a questionnaire between 2000 and 2002, and 674 incidental colorectal cancer cases were identified through 2010. Results: In stratified analysis, high use of any type of NSAIDs (4+days/week for 4+ years) was statistically significantly associated with a lower risk of CRC across all subgroups stratified by sex, BMI, physical activity, smoking, alcohol intake, screening and dietary factors, with a suggestion of stronger association among men, obese individuals, and heavier drinkers; however, none of these tests for interaction reached statistical significance. The associations were almost identical for subjects with higher overall CRC risk scores (HR: 0.62; 95% CI: 0.49-0.79) and those with lower risk scores (HR: 0.61; 95% CI: 0.42-0.88). Differential effects by cancer subsites and stages were tested. NSAID use was associated with a greater risk reduction of proximal colon cancer vs distal (p for difference = 0.06) and distant stage vs local (p for difference = 0.04). Conclusion: The association between high use of NSAIDs and CRC risk does not differ significantly among subgroups. Impact: Our results suggest that NSAIDs have a generally beneficial role in colorectal cancer prevention, largely unmodified by other exposures. Citation Format: Xiaoliang Wang, Ulrike Peters, John D. Potter, Emily White. Association of non-steroidal anti-inflammatory drugs with colorectal cancer by subgroups in the Vitamins and Lifestyle (VITAL) Study. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 862. doi:10.1158/1538-7445.AM2015-862
Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab.
Authors: Humaid O. Al-Shamsi, Mahraz Anjum, Abdulaziz Al Farsi, Hua Shen, Lori-Ann Linkins, Richard J. Cook, Pierre Major
Journal: Journal of Clinical Oncology (2013)

540 Background: The rate of venous thromboembolism (VTE) in (mCRC) with bevacizumab was reported in a meta-analysis as 19.1%. We estimated and compared the rate of VTE among mCRC patients receiving FOLFIRI and bevacizumab with patients receiving FOLFIRI without bevacizumab. Methods: We conducted a retrospective cohort study assessing the rate of VTE in a group of 450 mCRC patients seen consecutively at the Juravinski Cancer Center. Patients were classified according to their treatment: chemotherapy plus bevacizumab group (n=261) and control group (n=189) who received only FOLFIRI during the years 2004 to 2012. Demographic, pathologic and treatment data were abstracted. Multivariate analysis was used to adjust for the effect potential confounding variables associated with treatment and VTE and to assess the effect of these variables risk of VTEs in this population. The primary end point was the occurrence of a VTE. Secondary analyses involved classifying site of VTE. Results: The percentage of male, mean age and mean BMI were 64.8%, 60.1 years and 27.2 for the bevacizumab group and 61.9%, 63.69 years and 27.6 are for the control group. The crude incidence of VTEs was 13.1% in bevacizumab and 10.5% in the control groups (p = NS). Multivariate analysis controlled for age, BMI, gender, malignancy, metastatic disease and line of treatment did not suggest a significant increase in risk of VTE associated with bevacizumab (OR=0.83 95% CI: 0.40, 1.70; p=0.602). The only significant factor for thrombosis in bevacizumab group was BMI (OR=1.05; 95% CI: 1.01, 1.10; p=0.016). Other risk factors such as previous VTE, stroke, smoking, and hypertension were not statistically significant when assessed through a composite covariate. For anatomical location of VTEs, see the Table. Conclusions:The rate of VTEs overall was lower in our sample than has been reported in previous studies. We excluded upper limb DVTs associated with central lines which may explain the lower VTEs overall. The incidence of VTEs was not significantly different between the bevacizumab and the control groups. bevacizumab was not associated with increase risk of VTES . This support the safety of bevacizumab in regards to VTEs risk in this population. The incidence of venous thromboembolism (VTE) in FOLFIRI with and without bevacizumab. [Table: see text]
Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma
Authors: Deepak Perumal, Pei-Yu Kuo, Violetta V. Leshchenko, Zewei Jiang, Sai Krishna Athaluri Divakar, Hearn Jay Cho, Ajai Chari, Joshua Brody, M.V. Ramana Reddy, Weijia Zhang, E. Premkumar Reddy, Sundar Jagannath, Samir Parekh
Journal: Cancer Research (2016)

Multiple myeloma is a fatal plasma cell neoplasm accounting for over 10,000 deaths in the United States each year. Despite new therapies, multiple myeloma remains incurable, and patients ultimately develop drug resistance and succumb to the disease. The response to selective CDK4/6 inhibitors has been modest in multiple myeloma, potentially because of incomplete targeting of other critical myeloma oncogenic kinases. As a substantial number of multiple myeloma cell lines and primary samples were found to express AMPK-related protein kinase 5(ARK5), a member of the AMPK family associated with tumor growth and invasion, we examined whether dual inhibition of CDK4 and ARK5 kinases using ON123300 results in a better therapeutic outcome. Treatment of multiple myeloma cell lines and primary samples with ON123300 in vitro resulted in rapid induction of cell-cycle arrest followed by apoptosis. ON123300-mediated ARK5 inhibition or ARK5-specific siRNAs resulted in the inhibition of the mTOR/S6K pathway and upregulation of the AMPK kinase cascade. AMPK upregulation resulted in increased SIRT1 levels and destabilization of steady-state MYC protein. Furthermore, ON123300 was very effective in inhibiting tumor growth in mouse xenograft assays. In addition, multiple myeloma cells sensitive to ON123300 were found to have a unique genomic signature that can guide the clinical development of ON123300. Our study provides preclinical evidence that ON123300 is unique in simultaneously inhibiting key oncogenic pathways in multiple myeloma and supports further development of ARK5 inhibition as a therapeutic approach in multiple myeloma.
Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells.
Authors: M R Bishop, J D Jackson, B O'Kane-Murphy, K Schmit-Pokorny, J M Vose, P J Bierman, P I Warkentin, J O Armitage, L Garrison, A Kessinger
Journal: Journal of Clinical Oncology (1996)

PURPOSE Mobilization of peripheral-blood cells (PBC) with cytokines alone results in rapid hematopoietic recovery and avoids the potential morbidity associated with mobilization by chemotherapy. PIXY321, a fusion protein that consists of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), has enhanced hematopoietic colony-forming activity as compared with individual or equimolar combinations of the two cytokines. A phase I trial of PIXY321 for mobilization of PBC in patients with malignant lymphoma was performed. PATIENTS AND METHODS Thirteen patients with malignant lymphoma who were eligible for high-dose therapy (HDT) were enrolled onto the trial. All patients were ineligible for autologous bone marrow transplantation due to overt metastatic disease in the marrow or to severe marrow hypocellularity. PIXY321 was administered at three dose levels of 250, 500, and 750 micrograms/m2/d by continuous infusion until completion of PBC collections. Collections were initiated when the WBC count was greater than 10 x 10(9)/L or 4 days after the initiation of PIXY321, whichever came first. Collections were continued until a minimum of 6.5 x 10(8) mononuclear cells (MNC)/kg patient weight were obtained. RESULTS PIXY321 was generally well tolerated. Side effects associated with PIXY321 administration did not exceed grade 2 and included fever (85%), chills/sweats (54%), myalgias (38%), fatigue (31%), nausea/vomiting (31%), headache (31%), edema (23%), and rhinorrhea (23%). The median numbers of colony-forming units-granulocyte/macrophage (CFU-GM) in the graft products for the three dose levels were 0.31, 2.94, and 2.88 x 10(4)/kg, respectively; the median numbers of burst-forming units-erythroid (BFU-e) were 0.20, 6.94, and 12.78 x 10(4)/kg, and the median numbers of CD34+ cells were 2.30, 0.74, and 0.39 x 10(6)/kg. Following transplantation, the median times to an absolute neutrophil count (ANC) &gt; 0.5 x 10(9)/L were 12, 15, and 12 days, respectively, and the median times to platelet transfusion independence were 30, 19, and 15 days. CONCLUSION PIXY321 can be safely administered and effectively mobilizes PBC in patients with bone marrow defects. PIXY321-mobilized PBC autotransplants result in rapid and sustained hematopoietic recovery.
Studies of the Generalized Shwartzman Reaction Produced by Diet: IV Ethyl Ester Fractions of Cod Liver Oil and Dihydroxystearic Acid
Authors: H KAUNITZ, E GAUGLITZ, D G McKAY
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue